StockData

Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$92.48+3.18 (+3.56%)

Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%

Earnings

Dianthus Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 8, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$761.00K
+294.3% on a year earlier
EPS, Q2 FY2026
-$0.90
-$0.88 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Dianthus Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 8, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close–––Filing
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$761.00K+294.3%-$0.90Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours–––Release
Q4 FY2025ended Dec 31, 2025Mar 9, 2026before the open$284.00K-78.6%-$1.43Release
Q3 FY2025ended Sep 30, 2025Oct 16, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$193.00K-89.6%-$0.88Release
Q1 FY2025ended Mar 31, 2025May 12, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025during market hours$1.33M+189.9%-$0.81Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$2.17M+135.1%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$1.86M–-$0.51Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours$874.00K–-$0.54Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Dianthus Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Dianthus Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Dianthus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
    Results
  2. Advancing a leading autoimmune-focused company June 2026 Exhibit 99.1
    News
  3. DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
    Results
  4. Advancing a leading autoimmune-focused company March 2026 Exhibit 99.1
    News
  5. DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS, INCLUDING GO DECISION FOR PHASE 3 CAPTIVATE CIDP TRIAL,
    Results
  6. DIANTHUS THERAPEUTICS ANNOUNCES EARLY GO DECISION FOLLOWING INTERIM RESPONDER ANALYSIS IN PHASE 3 CAPTIVATE TRIAL OF CLASEPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
    Results
  7. Dianthus Therapeutics Early GO Decision in CAPTIVATE CIDP Trial March 9, 2026 Exhibit 99.3
    Results
  8. Advancing a leading autoimmune-focused company January 2026 Exhibit 99.1
    Results
  9. DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
    Results
  10. Corporate Presentation November 2025 Exhibit 99.1
    News
  11. Dianthus Therapeutics Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs October 16, 2025 Exhibit 99.1
    Results
  12. DIANTHUS THERAPEUTICS ANNOUNCES POSITIVE DATA FOR CLASEPRUBART (DNTH103) FROM THE PHASE 2 MAGIC TRIAL IN
    Update
  13. Claseprubart (DNTH103) Top-line Ph. 2
    Update
  14. DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
    Results
  15. DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
    Results

See a number that looks wrong?